SOBI — Swedish Orphan Biovitrum AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK165.02bn
- SEK180.18bn
- SEK28.24bn
US FDA approves Sanofi's drug for a rare blood disorder
Brief: SOBI Announces U.S. Food And Drug Administration Approves Doptelet For The Treatment Of Thrombocytopenia In Pediatric Patients One Year And Older With Persistent Or Chronic Immune Thrombocytopenia
Europe Research Roundup: Antofagasta, Burberry, SEB
Media: Swedish drugmaker Sobi doesn't see pharma tariffs as ‘imminent’- Bloomberg News
Brief: SOBI Keeps 2025 Outlook Unchanged
Earnings Poll: Swedish Orphan Biovitrum second quarter results due on July 16
Top of the Street: Handelsbanken, Arkema, Zealand Pharma, SOBI, Argenx
DB expects EU pharma 'malaise' to continue amid US headwinds
Brief: Swedish Orphan Biovitrum To Amend Agreement With Apellis
Brief: Biovitrum Says FDA Approves Gamifant® Treatment For Adults And Children With Macrophage Activation Syndrome In Still's Disease
Europe Research Roundup: AB Foods, Jet2, THG
Brief: SOBI 2025 Outlook Unchanged
Europe Research Roundup: Antofagasta, Fraport, Man Group
Europe Research Roundup: Bunzl, LVMH, Tesco
Europe Research Roundup: BASF SE, Direct Line Insurance, Glencore
Brief: Swedish Orphan Biovitrum Proposes No Dividend Is Paid For 2024
Brief: SOBI Q4 EBIT SEK 1,662 Million Vs. IBES Estimate SEK 1,836 Million
Earnings Poll: Swedish Orphan Biovitrum fourth quarter results due on February 5
Barclays cautious on European pharma in H1, sees re-rating chance in H2